The global pneumococcal vaccine market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market includes the increasing efforts to curb pneumonia among children in developed countries. Whereas, in the developing countries, the increasing spending on infrastructure and rising awareness towards vaccines, are the factors, which are expected to fuel the market growth during the forecasted period.
A full report of Pneumococcal Vaccine Market is available at: https://www.omrglobal.com/industry-reports/pneumococcal-vaccine-market-share
According to the report by Jon Hopkins, in 2019, 5 million children died before reaching the age of 5 years, out of which around 25% of children died due to pneumonia or diarrhoea. The developing countries in Asia and Africa contribute to around 70% of the global death burden of children due to pneumonia. GAVI (the vaccine alliance) is working towards vaccinating these children who are living in emerging economies. For many countries including the UK, Canada, Russia, Norway, Bill Gates and Melinda Gates Foundation had contributed around $1.5 billion towards the program. By the end of 2018, more than 183 million children were given shot of the vaccine against pneumococcal.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pneumococcal-vaccine-market-share
Some of the key global market players include Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Walvax Biotechnology Co., Ltd., CSL Ltd., and Astellas Pharma Inc. In June 2020, the Serum Institute of India started supplying vaccines for $2 as compared to $3.5 per dose earlier. The company had agreed to provide 10 million doses per year to the countries which are supported by GAVI for the next 10 years.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Vaccine Type
o By Distribution Channel
o By Type
o By Age Group
- Competitive Landscape – Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Walvax Biotechnology Co., Ltd., CSL Ltd., among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Pneumococcal Vaccine Market by Segment
By Vaccine Type
- Pneumococcal Conjugate Vaccine (PCV13)
- Pneumococcal Polysaccharide Vaccine (PPSV23)
By Distribution Channel
- Public
- Private
By Type
- Branded
- Generic
By Age Group
- Children
- Adult
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
